G
Gerd Otto
Researcher at University of Mainz
Publications - 261
Citations - 10058
Gerd Otto is an academic researcher from University of Mainz. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 51, co-authored 261 publications receiving 9390 citations. Previous affiliations of Gerd Otto include University Hospital Heidelberg & University of Ulm.
Papers
More filters
Journal ArticleDOI
Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?
Susanne Strand,Walter J. Hofmann,Hubert Hug,Martina Müller,Gerd Otto,Dennis Strand,Sara M. Mariani,Wolfgang Stremmel,Peter H. Krammer,Peter R. Galle +9 more
TL;DR: The data suggest that tumor cells can evade immune attack by down–regulation of the CD95 receptor and killing of lymphocytes through expression of CD95L, which is an important mediator of T–cell cytotoxicity.
Journal ArticleDOI
Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage.
Peter R. Galle,Walter J. Hofmann,Henning Walczak,Heinz Schaller,Gerd Otto,Wolfgang Stremmel,Peter H. Krammer,Laura Runkel +7 more
TL;DR: The findings suggest that liver destruction in hepatitis B may primarily involve killing of hepatocytes by T lymphocytes using the CD95 receptor-ligand system.
Journal ArticleDOI
Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma
Gerd Otto,Sascha Herber,Michael Heise,Ansgar W. Lohse,Christian Mönch,Fernando Bittinger,Maria Hoppe-Lotichius,Marcus Schuchmann,Anja Victor,Michael B. Pitton +9 more
TL;DR: Sustained response to TACE is a better selection criterion for LT than the initial assessment of tumor size or number, according to the multivariate analysis.
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis.
Susanne Strand,Walter J. Hofmann,A Grambihler,Hubert Hug,Martin Volkmann,Gerd Otto,Horst Wesch,Sara M. Mariani,Volker Hack,Wolfgang Stremmel,Peter H. Krammer,Peter R. Galle +11 more
TL;DR: In patients with fulminant hepatic failure in the course of Wilson's disease and in an in vitro model of copper treated human hepatoma cells, copper overload in vitro resulted in hepatocytic apoptosis which could be reduced with a neutralizing anti-CD95L antibody.